biotech · Breast Cancer · Pleural carcinosis · SANA
Sana Biotechnology
Sana Biotechnology is a biotech organization headquartered in Seattle, USA. It trades on NYSE under ticker SANA. Primary therapeutic focus areas include Breast Cancer, Pleural carcinosis, Parkinson’s Disease, Graves' dis
188 E Blaine St, Suite 400, Seattle, Washington 98102, US HQ
2018 Founded
265 Employees
Public company Type
SANA · NYSE Ticker
Company details
- Status
- Public
- HQ
- 188 E Blaine St, Suite 400, Seattle, Washington 98102, US
- Founded
- 2018
- Employees
- 265
- Programs
- 19
- Drugs
- 22
- Patents
- 136
Myocet (Non-pegylated liposomal doxorubicin (NPLD))
Phase 2 · small molecule · Breast Cancer
Myocet (Non-pegylated liposomal doxorubicin (NPLD)) for Breast Cancer is a Phase 2 program (small_molecule) at Sana Biotechnology with 1 ClinicalTrials.gov record(s).
Internal code LAPADO-Study
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Sana Biotechnology
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Breast Cancer
- Status
- completed
- Trials
- 1